Pediatric GLP-1 Cost 2026 — Wegovy and Saxenda for Adolescents

STEP TEENS changed the conversation

Before 2023, pediatric obesity pharmacotherapy was a niche intervention. STEP TEENS showed 16.1% mean TBWL at 68 weeks on Wegovy 2.4 mg in adolescents 12–18 with obesity — numerically better than the adult STEP 1 result. The AAP’s 2023 clinical practice guideline incorporated GLP-1 therapy into standard-of-care for adolescent obesity alongside intensive health behavior and lifestyle treatment.

Cost paths in 2026

• Commercial insurance + savings card: $25/mo typical copay if the plan covers pediatric AOMs.
• Medicaid: State-dependent. Many states cover post-STEP TEENS.
• NovoCare self-pay vial (Wegovy): $499/mo. Available regardless of patient age.
• Uninsured retail: ~$1,300–$1,349/mo.
• Saxenda: same list price, daily injection rather than weekly.

Clinical framework

1. Diagnosis of obesity per pediatric BMI percentile.
2. Baseline labs: A1C, fasting glucose, lipids, LFTs, TSH, CBC.
3. Comorbidity screening: T2D, pre-diabetes, OSA, NAFLD, HTN, dyslipidemia, PCOS.
4. Mental health screening — eating disorder history is a contraindication.
5. Baseline dietitian visit and behavioral therapy referral.
6. Shared decision-making with patient and parent(s).

Monitoring cadence

During titration (first 20 weeks): every 4 weeks including weight, BMI percentile, side-effect screen, nutritional adequacy check. At maintenance: every 3 months. Labs every 6 months. Growth velocity at every visit — you’re looking for BMI percentile improvement without stalling linear growth.

Family considerations

Adolescent GLP-1 therapy works best when the family nutritional environment supports it. Stock high-protein foods accessible to the teen; reduce ultra-processed hyperpalatable foods at home; family mealtimes protect structure. Parent weight-loss journeys often parallel the adolescent’s — in some clinics 40%+ of parents enroll in adult obesity medicine after a child’s diagnosis.